|
|
Áèáëèîòåêà (ñòàòèñòèêà, äîêóìåíòû, ññûëêè):
Ïðîôèëàêòèêà ïåðåäà÷è ÂÈ× îò ìàòåðè ê ðåáåíêó
>>
Ðåêîìåíäàöèè ñïåöèàëüíîé ãðóïïû Ñëóæáû çäðàâîîõðàíåíèÿ ê ïðèìåíåíèþ àíòèðåòðîâèðóñíûõ
ïðåïàðàòîâ äëÿ ëå÷åíèÿ ÂÈ×-èíôèöèðîâàííûõ áåðåìåííûõ æåíùèí â öåëÿõ îõðàíû çäîðîâüÿ
ìàòåðè è ðåáåíêà è ñíèæåíèÿ ðèñêà ïåðèíàòàëüíîé ïåðåäà÷è ÂÈ×-1 â ÑØÀ (30 àâãóñòà
2002 ã.)
Ðåêîìåíäàöèè ñïåöèàëüíîé ãðóïïû Ñëóæáû çäðàâîîõðàíåíèÿ ê ïðèìåíåíèþ àíòèðåòðîâèðóñíûõ
ïðåïàðàòîâ äëÿ ëå÷åíèÿ ÂÈ×-èíôèöèðîâàííûõ áåðåìåííûõ æåíùèí â öåëÿõ îõðàíû çäîðîâüÿ
ìàòåðè è ðåáåíêà è ñíèæåíèÿ ðèñêà ïåðèíàòàëüíîé ïåðåäà÷è ÂÈ×-1 â ÑØÀ (30 àâãóñòà
2002 ã.)
Ñïèñîê ëèòåðàòóðû
1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission
of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med,
1994. 331(18):1173–80.
2. CDC. Recommendations of the Public Health Service Task Force on use of zidovudine
to reduce perinatal transmission of human immunodeficiency virus. MMWR, 1994.
43 (No. RR-11):1–20.
3. CDC. U.S. Public Health Service recommendations for human immunodeficiency
virus counseling and voluntary testing for pregnant women. MMWR, 1995. 44 (No.
RR-7):1–15.
4. Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing
pattern of zidovudine use during pregnancy, and the subsequent reduction in
vertical transmission of human immunodeficiency virus in a cohort of infected
women and their infants. J Infect Dis, 1996. 174(6):1207-11.
5. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and
the effect of zidovudine therapy on transmission in rural and urban counties.
JAMA, 1996. 275(19):1483–8.
6. Fiscus SA, Adimora AA, Funk ML, et al. Trends in interventions to reduce
perinatal human immunodeficiency virus type 1 transmission in North Carolina.
Pediatr Infect Dis J, 2002. 21:664–8.
7. Thomas P, Singh T, Bornschlegel K, et al. Use of ZDV to prevent perinatal
HIV in New York City (NYC) [Abstract]. Proceedings from the 4th Conference on
Retroviruses and Opportunistic Infections. Washington, DC. January 22-26, 1997
(Abstract 176).
8. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine
for prevention of mother-to-child human immunodeficiency virus-1 transmission
in France. J Pediatr, 1997. 131(6):857–62.
9. Harris NH, Thompson SJ, Ball R, et al. Zidovudine and perinatal human immunodeficiency
virus type 1 transmission: a population-based approach. Pediatrics, 2002. 109(4):
e60. URL:
http://www.pediatrics.org/cgi/content/full/109/4/e60.
10. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion
clearance rate, infected cell life span, and viral generation time. Science,
1996. 271(5255):1582–6.
11. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development
and therapeutic strategies. Ann Intern Med, 1996. 124(11):984–94.
12. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside
analogues plus indinavir in persons with human immunodeficiency virus infection
and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med, 1997.
337(11):725–33.
13. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine
and lamivudine in adults with human immunodeficiency virus infection and prior
antiretroviral therapy. N Engl J Med, 1997. 337(11):734–9.
14. CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. MMWR, 1998. 47 (RR-5):39–82 (and updates http://aidsinfo.nih.gov/).
15. Mofenson LM. Interaction between timing of perinatal human immunodeficiency
virus infection and the design of preventive and therapeutic interventions.
Acta Paediatr Suppl, 1997. 421:1–9.
16. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine
(AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer
Inst, 1997. 89 (21):1602–8.
17. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J
Obstet Gynecol, 1997. 176(2):478–89.
18. Mills JL. Protecting the embryo from X-rated drugs. N Engl J Med, 1995.
333(2):124-5.
19. CDC. Pregnancy outcomes following systemic prenatal acyclovir exposure --
June 1, 1984–June 30, 1993. MMWR, 1993. 42(41):806–9.
20. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy:
maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative
HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS,1998. 12(18):F241–7.
21. The European Collaborative Study and the Swiss Mother + Child HIV Cohort
Study. Combination antiretroviral therapy and duration of pregnancy. AIDS, 2000.
14(18): 2913–20.
22. Martin R, Boyer P, Hammill H, et al. Incidence of premature birth and neonatal
respiratory disease in infants of HIV-positive mothers. The Pediatric Pulmonary
and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency
Virus Infection Study Group. J Pediatr, 1997. 131(6): 851–6.
23. Leroy V, Ladner J, Nyiraziraje M, et al. Effect of HIV-1 infection on pregnancy
outcome in women in Kigali, Rwanda, 1992–1994. Pregnancy and HIV Study Group.
AIDS, 1998. 12(6): 643–50.
24. Brocklehurst P, French R. The association between maternal HIV infection
and perinatal outcome: a systematic review of the literature and meta-analysis.
Br J Obstet Gynaecol, 1998. 105(8): 836-48.
25. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine
combination for prevention of maternal-infant transmission of HIV-1. JAMA, 2001.
285(16):2083–93.
26. Tuomala RE, Shapiro D, Mofenson LM, et al. Antiretroviral therapy during
pregnancy and the risk of adverse outcome. N Engl J Med, 2002. 346:1863–70.
27. Food and Drug Administration. FDA Public Health Advisory: reports of diabetes
and hyperglycemia in patients receiving protease inhibitors for treatment of
human immunodeficiency virus (HIV). Food and Drug Administration, Public Health
Service, Department of Health and Human Services. Rockville, MD: June 11,1997.
28. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease
inhibitor therapy [letter]. Ann Intern Med, 1997. 127(10):947.
29. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of
protease inhibitor [letter]. Ann Intern Med, 1997. 127(10):948.
30. Dube MP, Sattler FR. Metabolic complications of antiretroviral therapies.
AIDS Clinical Care, 1998. 10(6):41–4.
31. Brinkman K, Ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse
transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS, 1998.
12(14):1735–44.
32. Martin JL, Brown DE, Matthews-Davis N, Reardon JE. Effects of antiviral
nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis.
Antimicrob Agents Chemother, 1994. 38 (12):2743–9.
33. Boxwell DE, Styrt BA. Lactic acidosis (LA) in patients receiving nucleoside
reverse transcriptase inhibitors (NRTIs). 39th Interscience Conference on Antimicrobial
Agents and Chemotherapy. San Francisco, CA, September 26–29, 1999. (Abstract
1284).
34. Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder
as a cause of liver disease in pregnant women. N Engl J Med, 1999. 340(22):1723–31.
35. Strauss AW, Bennett MJ, Rinaldo P, et al. Inherited long-chain 3-hydroxyacyl-CoA
dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver
disease and other pregnancy complications. Semin Perinatol, 1999. 23(2):100–12.
36. Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric
long-chain 3-hydroxyacyl Co-A dehydrogenase deficiency associated with maternal
acute fatty liver of pregnancy. Proc Natl Acad Sci USA, 1995. 92 (3):841–5.
37. Ibdah JA, Yang Z, Bennett MJ. Liver disease in pregnancy and fetal fatty
acid oxidation defects. Mol Genet Metab, 2000. 71(1–2):182–9.
38. Grimbert S, Fromenty B, Fisch C, et al. Decreased mitochondrial oxidation
of fatty acids in pregnant mice: possible relevance to development of acute
fatty liver of pregnancy. Hepatology, 1993. 17(4): 628–37.
39. Grimbert S, Fisch C, Deschamps D, et al. Effects of female sex hormones
on mitochondria: possible role in acute fatty liver of pregnancy. Am J Physiol,
1995. 268(1 Pt 1):G107–15.
40. Fortgang IS, Belitsos PC, Chaisson RE, et al. Hepatomegaly and steatosis
in HIV-infected patients receiving nucleoside analogue antiretroviral therapy.
Am J Gastroenterol, 1995. 90(9):1433–6.
41. Gerard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: an
emerging complication of antiretroviral therapy. AIDS, 2000. 14(17):2723–30.
42. Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic
acidosis. Lancet, 1999. 353(9156):901–2.
43. Bristol-Myers Squibb Company. Healthcare Provider Important Drug Warning
Letter. January 5, 2001.
44. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction
and perinatal exposure to antiretroviral nucleoside analogues. Lancet, 1999.
354(9184):1084–9.
45. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant
zidovudine regimen utilized in the Pediatric AIDS Clinical Trials Group 076
Study. AIDS, 1998. 12(14):1805–13.
46. The Perinatal Safety Review Working Group. Nucleoside exposure in the children
of HIV-infected women receiving antiretroviral drugs: absence of clear evidence
for mitochondrial disease in children who died before 5 years of age in five
United States cohorts. J Acquir Immune Defic Syndr Hum Retrovirol, 2000. 25(3):261–8.
47. Lange J, Stellato R, Brinkman K, et al. Review of neurological adverse events
in relation to mitochondrial dysfunction in the prevention of mother to child
transmission of HIV: PETRA study. 2nd Conference on Global Strategies for the
Prevention of HIV Transmission from Mothers to Infants. September 1–6, 1999,
Montreal, Canada. (Abstract 250).
48. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of
zidovudine in infants. N Engl J Med, 2000. 343(11):759–66.
49. Morris AA, Carr A. HIV nucleoside analogues: new adverse effects on mitochondria?
Lancet, 1999. 354(9184):1046–7.
50. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine
treatment, and the risk of transmission of human immunodeficiency virus type
1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study
Group. N Engl J Med, 1996. 335(22):1621–9.
51. Sandberg JA, Binienda Z, Lipe G, et al. Placental transfer and fetal disposition
of 2`,3`-dideoxycytidine and 2`, 3`-dideoxyinosine in the rhesus monkey. Drug
Metab Dispos, 1995. 23(8):881–4.
52. Qian M, Bui T, Ho RJY, Unadkat JD. Metabolism of 3'-azido-3'-deoxythymidine
(AZT) in human placental trophoblasts and hofbauer cells. Biochem Pharmacol,
1994. 48(2):383–9.
53. Dancis J, Lee JD, Mendoza S, Liebes L. Transfer and metabolism of dideoxyinosine
by the perfused human placenta. J Acquir Immune Defic Syndr Hum Retrovirol,
1993. 6(1):2–6.
54. Sandberg JA, Binienda Z, Lipe G, Slikker Jr W. Placental transfer and fetal
disposition of dideoxycytidine (ddC) and dideoxyinosine (ddI) [Abstract]. Toxicologist,
1994. 14:434.
55. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy
Registry International Interim Report for 1 January 1989 through 31 January
2002. Wilmington, NC: Registry Coordinating Center; 2002.
56. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero
exposure to zidovudine among uninfected children born to HIV-infected women.
JAMA, 1999. 281(2):151–7.
57. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with
perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir
Immune Defic Syndr Hum Retrovirol, 1999. 20(5):463–7.
58. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and hyperimmune
human immunodeficiency virus (HIV) immunoglobulin for reducing perinatal HIV
transmission from HIV-infected women with advanced disease: results of Pediatric
AIDS Clinical Trials Group Protocol 185. J Infect Dis, 1999. 179(3):567–75.
59. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies
for the treatment of pregnant HIV-1 infected women and prevention of perinatal
HIV-1 transmission. J Acquir Immune Defic Syndr Hum Retrovirol, 2002. 29(5):484–94.
60. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal
HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet,
1999. 353(9155):773–80.
61. Lallemant M, Jourdain G, Kim S, et al. A trial of shortened zidovudine regimens
to prevent mother-to-child transmission of human immunodeficiency virus type
1. N Engl J Med, 2000. 343(14):982–91.
62. The Petra Study Team. Efficacy of three short-course regimens of zidovudine
and lamivudine in preventing early and late transmission of HIV-1 from mother
to child in Tanzania, South Africa, and Uganda (Petra Study): a randomised,
double-blind, placebo-controlled trial. Lancet, 2002. 359(9313):1178–86.
63. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose
nevirapine compared with zidovudine for prevention of mother-to-child transmission
of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet, 1999. 354
(9181):795–802.
64. Moodley D. The SAINT Trial: nevirapine (NVP) versus zidovudine (ZDV) + lamivudine
(3TC) in prevention of peripartum HIV Transmission. 13th International AIDS
Conference. Durban, South Africa. July 2001. (Abstract LbOr2).
65. Lallemant M, Jourdain G, Le Coeur S, et al. Nevirapine (NVP) during labor
and in the neonate significantly improves zidovudine (ZDV) prophylaxis for the
prevention of perinatal HIV transmission: results of PHPT-2 first interim analysis.
14th International AIDS Conference. Barcelona, Spain, July 7-12, 2002. Abs.
LbOr22.
66. Dabis F, Leroy V, Bequet L, et al. Effectiveness of a short course of zidovudine
+ nevirapine to prevent mother-to-child transmission (PMTCT) of HIV-1: The Ditrame
Plus ANRS 1201 Project in Abidjan, Cote d'Ivoire. 14th International AIDS Conference.
Barcelona, Spain, July 7–12, 2002. Abs. ThOrD1428.
67.Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn
nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission:
a randomized trial. JAMA, 2002. 288(2):189–98.
68. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine
prophylaxis and perinatal transmission of the human immunodeficiency virus.
N Engl J Med, 1998. 339(20):1409–14.
69. Shaffer N, Bulterys M, Simonds RJ. Short courses of zidovudine and perinatal
transmission of HIV. N Engl J Med, 1999. 340(13):1042–3.
70. CDC. Case-control study of HIV seroconversion in health-care workers after
precutaneous exposure to HIV-infected blood -- France, United Kingdom, and United
States, January 1988 August 1994. MMWR, 1995. 44:929–33.
71. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical
transmission of infection: The Ariel Project for the prevention of HIV transmission
from mother to infant. Nat Med, 1997. 3(5):549–52.
72. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of
maternal HIV-1 RNA associated with risk of perinatal transmission: effect of
maternal zidovudine treatment on viral load. JAMA, 1996. 275(8): 599–605.
73. Mayaux MJ, Dussaix E, Isopet J, et al. Maternal virus load during pregnancy
and the mother-to- child transmission of human immunodeficiency virus type 1:
the French Perinatal Cohort Studies. J Infect Dis, 1997. 175(1):172–5.
74. Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load
on the risk of perinatal transmission of HIV-1. AIDS, 1997. 11(4):437ì44.
75. Shapiro DE, Sperling RS, Coombs RW. Effect of zidovudine on perinatal HIV-1
transmission and maternal viral load. Lancet, 1999. 354(9173):156; discussion
157–8.
76. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission
of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric
AIDS Clinical Trials Group Study 185 Team. N Engl J Med, 1999. 341 (6):385–93.
77. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency
virus type 1 RNA and the risk of perinatal transmission. N Engl J Med, 1999.
341(6):394–402.
78. The European Collaborative Study. Maternal viral load and vertical transmission
of HIV-1: an important factor but not the only one. AIDS, 1999. 13(11):1377–85.
79. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of
mother-to-child HIV transmission, Bangkok, Thailand. AIDS, 1999. 13(3):407–14.
80. Shaffer N, Roongpisuthipong A, Siriwasin W, et al. Maternal virus load and
perinatal human immunodeficiency virus subtype E transmission, Thailand. J Infect
Dis, 1999. 179(3):590–9.
81. Hart CE, Lennox JL, Pratt-Palmore M, et al. Correlation of human immunodeficiency
virus type 1 RNA levels in blood and the female genital tract. J Infect Dis,
1999. 179(4):871–82.
82. Iverson AKN, Larsen AR, Jensen T, et al. Distinct determinants of human
immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions.
J Infect Dis, 1998. 177(5):1214–20.
83. Shaheen F, Sison AV, McIntosh L, et al. Analysis of HIV-1 in cervicovaginal
secretions and blood of pregnant and non-pregnant women. J Hum Virol, 1999.
2(3):154–66.
84. Rasheed S, Li Z, Xu D, Kovacs A. Presence of cell-free human immunodeficiency
virus in cervicovaginal secretions is independent of viral load in the blood
of human immunodeficiency virus-infected women. Am J Obstet Gynecol, 1996. 175(1):
122–9.
85. Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine
reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and
risk of perinatal transmission. J Infect Dis, 2000. 181(1):99–106.
86. McGowan JP, Crane M, Wiznia AA, Blum S. Combination antiretroviral therapy
in human immunodeficiency virus-infected pregnant women. Obstet Gynecol, 1999.
94(5):641–6.
87. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine
therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum
Retrovirol, 1997. 14(3):232–6.
88. Ioannidis JPA, Abrams EJ, Ammann A, et al. Perinatal transmission of human
immunodeficiency virus type 1 by pregnant women with RNA virus loads < 1000
copies/mL. J Infect Dis, 2001. 183(4):539–45.
89. Tuomala R, Shapiro D, Samelson R, et al. Antepartum antiretroviral therapy
and viral load in 464 HIV-infected women in 1998-1999 (PACTG 367). Am J Obstet
Gynecol, 2000. 182 (part 2): Abstract 285.
90. American College of Obstetricians and Gynecologist Technical Bulletin. Preconceptional
Care. Number 205, May1995.
91. Burns DN, Landesman S, Muenz LR, et al. Cigarette smoking, premature rupture
of membranes and vertical transmission of HIV-1 among women with low CD4+ levels.
J Acquir Immune Defic Syndr Hum Retrovirol, 1994. 7(7):718–26.
92. Turner BJ, Hauck WW, Fanning R, Markson LE. Cigarette smoking and maternal-child
HIV transmission. J Acquir Immune Defic Syndr Human Retrovirol, 1997. 14(4):327–37.
93. Rodriguez EM, Mofenson LM, Chang BH, et al. Association of maternal drug
use during pregnancy with maternal HIV culture positivity and perinatal HIV
transmission. AIDS, 1996. 10(3):273–82.
94. Bulterys M, Landesman S, Burns DN, et al. Sexual behavior and injection
drug use during pregnancy and vertical transmission of HIV-1. J Acquir Immune
Defic Syndr Human Retrovirol, 1997. 15(1):76–82.
95. Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavior during pregnancy
and perinatal transmission of HIV-1. AIDS, 1996. 10(11):1249–56.
96. CDC. Recommendations for assisting in the prevention of perinatal transmission
of human T-lymphotropic virus type III/lymphadenopathy-associated virus and
acquired immunodeficiency syndrome. MMWR, 1985. 34(48):721-6, 731–2.
97. Rodman JH, Robbins BL, Flynn PM, Fridland A. A systemic and cellular model
for zidovudine plasma concentrations and intracellular phosphorylation in patients.
J Infect Dis, 1996. 174(3):490–9.
98. Barry MG, Khoo SH, Veal GJ, et al. The effect of zidovudine dose on the
formation of intracellular phosphorylated metabolites. AIDS, 1996. 10(12):1361–7.
99. Peter K, Gambertoglio JG. Zidovudine phosphorylation after short term and
long/term therapy with zidovudine in patients infected with the human immuno-deficiency
virus. Clin Pharmacol Therapy, 1996. 60(2):168–76.
100. Mulder JW, Cooper DA, Mathiesen L, et al. Zidovudine twice daily in asymptomatic
subjects with HIV infection and a high risk of progression to AIDS: a randomized,
double-blind placebo-controlled study. AIDS, 1994. 8(3):313–21.
101. Mannucci PM, Gringeri A, Savidge G, et al. Randomized double-blind, placebo-controlled
trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with
the human immunodeficiency virus type 1. Brit J Haematol, 1994. 86(1):174–9.
102. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic
HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N
Engl J Med, 1993. 329(5):297–303.
103. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine
administered to infants exposed at birth to the human immunodeficiency virus.
J Pediatr, 1993. 122(1):137-44.
104. Mirochnick M, Capparelli E, Dankner W, et al. Zidovudine pharmacokinetics
in premature infants exposed to human immunodeficiency virus. Antimicrobial
Agents Chemother, 1998. 42(4):808–12.
105. Clarke JR, Braganza R, Mirza A, et al. Rapid development of genotypic resistance
to lamivudine when combined with zidovudine in pregnancy. J Med Virol, 1999.
59(3):364–8.
106. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine
resistance and infrequent failure of zidovudine therapy to prevent perinatal
transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical
Trial Group Protocol 076. J Infect Dis, 1998. 177(3):557–64.
107. Miotti PG, Taha TET, Kumwenda NI, et al. HIV transmission through breastfeeding
— a study in Malawi. JAMA, 1999. 282(8):744–9.
108. Koup RA, Brewster F, Grob P, Sullivan JL. Nevirapine synergistically inhibits
HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin.
AIDS, 1993. 7(9):1181–4.
109. Musoke P, Guay L, Bagenda D, et al. A phase I/II study of the safety and
pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and
their neonates (HIVNET 006). AIDS, 1999. 13(4):479–86.
110. Zhang H, Dornadula G, Wu Y, et al. Kinetic analysis of intravirion reverse
transcription in the blood plasma of human immunodeficiency virus type 1-infected
individuals: direct assessment of resistance to reverse transcriptase inhibitors
in vivo. J Virol, 1996. 70(1):628–34.
111. Frenkel LM, Wagner LE, Demeter LM, et al. Effects of zidovudine use during
pregnancy on resistance and vertical transmission of human immunodeficiency
virus type 1. Clin Infect Dis, 1995. 20(5):1321–6.
112. Wainberg MA, Friedland G. Public health implications of antiretroviral
therapy and HIV drug resistance. JAMA, 1998. 279(24):1977–83.
113. Kully C, Yerly S, Erb P, et al. Codon 215 mutations in human immunodeficiency
virus-infected pregnant women. J Infect Dis, 1999. 179(3):705–8.
114. Colgrove RC, Pitt J, Chung PH, et al. Selective vertical transmission of
HIV-1 antiretroviral resistance mutations. AIDS, 1998. 12(17):2281–8.
115. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations
among pregnant human immunodeficiency virus type 1-infected women and their
newborns in the United States: vertical transmission and clades. J Infect Dis,
2001. 184(9):1120-6.
116. Van Rompay KK, Otsyula MG, Marthas ML, et al. Immediate zidovudine treatment
protects simian immunodeficiency virus-infected newborn macaques against rapid
onset of AIDS. Antimicrob Agents Chemother, 1995. 39(1):125–31.
117. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques
by (R)-9-(2- phosphonylmethoxypropyl)adenine. Science, 1995. 270(5239):1197–9.
118. Bottiger D, Johansson NG, Samuelsson B, et al. Prevention of simian immunodeficiency
virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure
administration of BEA-005. AIDS, 1997. 11(2):157–62.
119. Mathes LE, Polas PJ, Hayes KA, et al. Pre- and post-exposure chemoprophylaxis:
evidence that 3'-azido-3'dideoxythymidine (AZT) inhibits feline leukemia virus
disease by a drug-induced vaccine response. Antimicrob Agents Chemother, 1992.
36(12):2715–21.
120. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase
chain reaction in the neonatal period and the relative contributions of intra-uterine
and intra-partum transmission. AIDS, 1995. 9(9):F7–11.
121. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated
with reduced antiretroviral drug susceptibility among human immunodeficiency
virus type 1 seroconverters in the United States, 1993–1998. J Infect Dis, 2000.
182(1):330–3.
122. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility
among patients with primary HIV infection. JAMA, 1999. 282(12):1142–9.
123. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected
individuals. JAMA, 1999. 282(12):1135–41.
124. Pomerantz RJ. Primary HIV-1 resistance: a new phase in the epidemic? JAMA,
1999. 282 (12):1177–9.
125. Welles SL, Pitt J, Colgrove R, et al. HIV-1 genotypic zidovudine drug resistance
and the risk of maternal-infant transmission in the Women and Infants Transmission
Study Group. AIDS, 2000. 14(3):263–71.
126. Sitnitskaya Y, Rochford G, Rigaud M, et al. Prevalence of the T215Y mutation
in human immunodeficiency virus type 1-infected pregnant women in a New York
cohort, 1995–1999. Clin Infect Dis, 2001. 33(1):e3–7.
127. Mofenson LM, Lambert J, Stiehm ER, et al. Case-control study of perinatal
HIV-1 transmission and genotypic and phenotypic markers of reduced susceptibility
to zidovudine (ZDV). 14th International Conference on AIDS. Barcelona, Spain.
July 7–12, 2002. (Abs. TuPeB4593).
128. Johnson VA, Woods C, Hamilton CD, et al. Vertical transmission of multi-drug-resistant
human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug
resistance in an HIV-1-infected infant. J Infect Dis, 2001. 183(11):1688–93.
129. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination
with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency
syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for
the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med,
1996. 335(15):1099–106.
130. Bardeguez A, Mofenson LM, Fowler M, et al. Lack of clinical or immunologic
disease progression with transient use of zidovudine (ZDV) to reduce perinatal
HIV transmission in PACTG 076. 12th World AIDS Conference. Geneva, Switzerland,
June 28–July 3, 1998. (Abstract 12233).
131. Clarke SM, Mulcahy F, Healy CM, et al. The efficacy and tolerability of
combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Internat J STD AIDS, 2000. 11(4):220–3.
132. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure
in previously untreated HIV-infected patients from a trial of induction-maintenance
therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team).
JAMA, 2000. 283(2):205–11.
133. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV
infection after viral rebound in patients receiving indinavir-containing regimens.
JAMA, 2000. 283(2):229–34.
134. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance
mutations in women and infants receiving nevirapine to prevent HIV-1 vertical
transmission (HIV-1NET 012). AIDS, 2001. 15(15):1951–7.
135. Cunningham CK, Chaix ML, Rekacewica C, et al. Development of resistance
mutations in women on standard antiretroviral therapy who received intrapartum
nevirapine to prevent perinatal HIV-1 transmission: a substudy of pediatric
AIDS clinical trials group protocol 316. J Infect Dis, 2002. 186(2):181–8.
136. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. for the International AIDS
Society-USA Panel. Antiretroviral drug resistance testing in adult HIV-1 infection:
recommendations of an International AIDS Society-USA Panel. JAMA, 2000. 283(18):2417–26.
137. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines
for the use of HIV-1 drug resistance testing as part of treatment management:
Recommendations for the European setting. AIDS, 2001. 15(3):309-20.
138. The International Perinatal HIV Group. The Mode of Delivery and the Risk
of Vertical Transmission of Human Immunodeficiency Virus Type 1— a Meta-Analysis
of 15 Prospective Cohort Studies. N Engl J Med, 1999. 340(13):977–87.
139. The European Mode of Delivery Collaboration. Elective cesarean-section
versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised
clinical trial. Lancet, 1999. 353(9158):1035–9.
140. ACOG committee opinion scheduled Cesarean delivery and the prevention of
vertical transmission of HIV infection. Number 234, May 2000 (replaces number
219, August 1999). Int J Gynaecol Obstet. 2001 Jun;73(3) 279–81.
141. Burns DN, Landesman S, Wright DJ, et al. Influence of other maternal variables
on the relationship between maternal virus load and mother-to-infant transmission
of human immunodeficiency virus type 1. J Infect Dis, 1997. 175(5):1206–10.
142. Coll O, Hernandez M, Boucher CA, et al. Vertical HIV-1 transmission correlates
with a high maternal viral load at delivery. J Acquir Immune Defic Syndr Hum
Retrovirol, 1997. 14(1):26–30.
143. Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: A prospective
cohort study of maternal-child transmission of human immunodeficiency virus
type 1 in the era of maternal antiretroviral therapy. J Infect Dis, 1999. 179(2):319–8.
144. Samelson R, Shapiro D, Tuomala RE, et al. HIV vertical transmission rates
according to antiretroviral therapy and viral load during pregnancy among 347
mother-child pairs 1998–99 (PACTG 367). Society for Maternal Fetal Medicine
Annual Meeting, Miami Beach, FL. Jan. 2000. (Abstract 276).
145. Beckerman KP, Morris AB, Stek A. Mode of delivery and the risk of vertical
transmission of HIV-1. (Letter). N Engl J Med, 1999. 341 (3):205–6.
146. Helfgott A, Eriksen N, Lewis S, et al. Highly active antiretroviral therapy
for the prevention of perinatal HIV. Society for Maternal Fetal Medicine Annual
Meeting, Miami Beach, FL. Jan. 2000. (Abstract 289).
147. Nielsen TF, Hokegard KH. Postoperative cesarean section morbidity: a prospective
study. Am J Obstet Gynecol, 1983. 146(8):911–5.
148. Hebert PR, Reed G, Entman SS, et al. Serious maternal morbidity after childbirth:
prolonged hospital stays and readmissions. Obstet Gynecol, 1999. 94(6):942–7.
149. Roman J, Bakos O, Cnattingius S. Pregnancy outcomes by mode of delivery
among term breech births: Swedish experience 1987–1993. Obstet Gynecol, 1998.
92(6):945–50.
150. Gregory KD, Henry OA, Ramicone E, et al. Maternal and infant complications
in high and normal weight infants by method of delivery. Obstet Gynecol, 1998.
92(4 Pt 1):507–13.
151. Schiff E, Friedman SA, Mashiach S, et al. Maternal and neonatal outcome
of 846 term singleton breech deliveries: seven-year experience at a single center.
Am J Obstet Gynecol, 1996. 175(1): 18–23.
152. Van Ham MA, van Dongen PWJ, Mulder J. Maternal consequences of caesarean
section. A retrospective study of intra-operative and postoperative maternal
complications of caesarean section during a 10-year period. Eur J Obstet Gynecol
Repro Biol, 1997. 74(1):1–6.
153. McMahon MJ, Luther ER, Bowes WA Jr., Olshan AF. Comparison of a trial of
labor with an elective second cesarean section. N Engl J Med, 1996. 335(10):689–95.
154. Watts DH, Lambert JS, Stiehm ER, et al. Complications according to mode
of delivery among human immunodeficiency virus infected women with CD4 lymphocyte
counts of < or =500/microL. Am J Obstet Gynecol, 2000. 183(1): 100–7.
155. Read JS, Tuomala R, Kpamegan E, et al. Mode of delivery and postpartum
morbidity among HIV-infected women: the Women and Infants Transmission Study.
J Acquir Immune Defic Syndr, 2001. 26(3): 236–45.
156. Marcollet A, Goffinet F, Firtion G, et al. Differences in postpartum morbidity
in women who are infected with the human immunodeficiency virus after elective
cesarean delivery, emergency cesarean delivery, or vaginal delivery. Am J Obstet
Gynecol, 2002. 186(4):784–9.
157. Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications
after caesarean section in 156 HIV-positive women. AIDS, 1995. 9(8): 913–7.
158. Grubert TA, Reindell D, Kastner R, et al. Complications after caesarean
section in HIV-1-infected women not taking antiretroviral treatment. Lancet,
1999. 354(9190):1612–3.
159. Maiques-Montesinos V, Cervera-Sanchez J, Bellver-Pradas J, et al. Post-cesarean
section morbidity in HIV-positive women. Acta Obstet Gynecol Scand, 1999. 78(9):789–92.
160. Vimercati A, Greco P, Loverro G, et al. Maternal complications after caesarean
section in HIV infected women. Europ J Obstet Gynecol Reprod Biol, 2000. 90(1):73–6.
161. Grubert TA, Reindell D, Kastner R, et al. Rates of postoperative complications
among human immunodeficiency virus-infected women who have undergone obstetric
and gynecologic surgical procedures. Clin Infect Dis, 2002. 34(6):822–30.
162. Rodriguez EJ, Spann C, Jamieson D, Lindsay M. Postoperative morbidity associated
with cesarean delivery among human immunodeficiency virus-seropositive women.
Am J Obstet Gynecol, 2001. 184(6):1108–11.
163. Urbani G, de Vries MMJ, Cronje HS, et al. Complications associated with
cesarean section in HIV-infected patients. Internatl J Gynecol Obstet, 2001.
74(1):9–15.
164. ACOG educational bulletin. Assessment of fetal lung maturity. Number 230,
November 1996. Committee on Educational Bulletins of the American College of
Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1996 Feb; 56(2):191–8.
165. Parilla BV, Dooley SL, Jansen RD, Socol ML. Iatrogenic respiratory distress
syndrome following elective repeat cesarean delivery. Obstet Gynecol, 1993.
81 (3):392-5.
166. Madar J, Richmond S, Hey E. Surfactant-deficient respiratory distress after
elective delivery at "term". Acta Paediatr, 1999. 88(11):1244–8.
167. ACOG educational bulletin. Antimicrobial therapy for obstetric patients.
Number 245, March 1998 (replaces no. 117, June 1988). American College of Obstetricians
and Gynecologists. Int J Gynaecol Obstet. 1988 Jun; 61(3):299–308.
168. Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration
of ruptured membranes to vertical transmission of human immunodeficiency virus.
Am J Obstet Gynecol, 1995. 173(2):585–9.
169. Landesman SH, Kalish LA, Burns DN, et al. Obstetrical factors and the transmission
of human immunodeficiency virus type 1 from mother to child. N Engl J Med, 1996.
334(25):1617–23.
170. Mandelbrot L, Mayaux MJ, Bongain A, et al. Obstetric factors and mother-to-child
transmission of human immunodeficiency virus type 1: The French Perinatal Cohorts.
SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol, 1996.
175(3 Pt 1):661–7.
171. Shapiro DE, Sperling RS, Mandelbrot L et al. Risk factors for perinatal
human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis.
Pediatric AIDS Clinical Trials Group protocol 076 Study Group. Obstet Gynecol,
1999. 94(6):897–908.
172. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal
transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy
and/or delivery. JAMA, 1994. 271(24):1925–30.
173. Kind C, Rudin C, Siegrist CA et al. Prevention of vertical HIV transmission:
additive protective effect of elective cesarean section and zidovudine prophylaxis.
AIDS, 1998. 12(2):205–10.
174. Miotti PG, Liomba G, Dallabetta GA, et al. T-lymphocyte subsets during
and after pregnancy: analysis in human immunodeficiency virus type 1-infected
and -uninfected Malawian mothers. J Infect Dis, 1992. 165(6):1116–9.
175. Tuomala RE, Kalish LA, Zorilla C, et al. Changes in total, CD4+, and CD8+
lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency
virus-infected women. Obstet Gynecol, 1997. 89(6):967–74.
176. CDC. 1995 revised guidelines for prophylaxis against Pneumocystis carinii
pneumonia for children infected with or perinatally exposed to human immunodeficiency
virus. MMWR, 1995. 44 (RR-4):1–11.
177. American Academy of Pediatrics, Committee on Pediatric AIDS. Evaluation
and medical treatment management of the HIV-exposed infant. Pediatrics, 1997.
99 (6):909–17.
178. Kovacs A, Xu J, Rasheed S, et al. Comparison of a rapid nonisotopic polymerase
chain reaction assay with four commonly used methods for the early diagnosis
of human immunodeficiency virus type 1 infection in neonates and children. Pediatr
Infect Dis J, 1995. 14(11):948–54.
179. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses.
Br J Psychiatry, 1987 May. 150: 662–73.
180. Ickovics JR, Wilson TE, Royce RA, et al. Prenatal and postnatal zidovudine
adherence among pregnant women with HIV. J Acquir Immune Defic Syndr, 2002.
30(3):311–5.
181. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor
therapy and outcomes in patients with HIV infection. Ann Intern Med, 2000. 133(1):21–30.
182. Richter A, Simpson KN, Manskopf JA. Impact of drug non-compliance and the
frequency of viral load testing on outcomes, costs and patterns of therapy.
12th World AIDS Conference. Geneva, 1998. (Abstract 42173).
183. Le Moing V, Masquelier B, Moatti JP, et al. To study predictors of immunologic
response to PI therapy, along with virologic response, including adherence to
therapy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy.
San Francisco, 1999. (Abstract 596).
184. Murri R, Ammasari A, Gallicano K, et al. Relationship of self-reported
adherence to HAART with protease inhibitor plasma level and viral load. 39th
Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco,
1999. (Abstract 593).
185. Miller L, Lui H, Beck K, et al. Providers estimates of adherence overestimate
reports from medication event monitoring (MEMS) for patients on protease inhibitors.
6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
(Abstract 97).
186. Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients
with HIV infection: A comparison of two measurement methods. The AIDS Reader,
1999. 9(5):329–38.
187. Dominguez K, Lindegren M, Fowler M, et al. Increasing trends in cesarean
sections in HIV-infected mothers of infants in the Pediatric Spectrum of HIV
Disease (PSD) cohort. 8th Conference on Retroviruses and Opportunistic Infections.
Chicago, IL, 2001. (Abstract 702).
188. The International Perinatal HIV Group. Duration of ruptured membranes and
vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies.
AIDS, 2001. 15(3):357–68.
Î ðàáîòå AFEW ïî ïðîôèëàêòèêå ïåðåäà÷è ÂÈ× îò ìàòåðè ê ðåáåíêó ñì.:
AFEW:
Ïðîåêòû
|
AFEW:
